Quick Answer
Tirzepatide is a dual GIP/GLP-1 receptor agonist — the first compound to simultaneously target both incretin receptors for synergistic metabolic research.
Tirzepatide is a 39-amino acid linear peptide with a C20 fatty diacid moiety for albumin binding. It represents a novel class of dual incretin receptor agonists, simultaneously engaging both GIP and GLP-1 receptors. GIP receptor activation potentiates GLP-1R-mediated effects and may directly modulate adipocyte lipid metabolism through distinct intracellular cascades. Research focuses on understanding the synergistic effects of dual receptor engagement versus single-target GLP-1R agonism (e.g., semaglutide).
Related Research Articles
More FAQs
BPC-157 is a synthetic 15-amino acid peptide fragment derived from human gastric juice protein, studied for tissue repair via VEGF upregulation and nitric oxide modulation.
What is Semaglutide?Semaglutide is a long-acting GLP-1 receptor agonist with 94% homology to native GLP-1, modified for extended half-life via albumin binding.
How do peptides work?Peptides are short chains of amino acids that bind specific receptors to trigger intracellular signaling cascades, modulating biological processes at the molecular level.
How should research peptides be stored?Lyophilized peptides should be stored at -20°C. Reconstituted peptides should be stored at 2–8°C and used within the specified stability window.
What does peptide purity mean?Peptide purity refers to the percentage of the target compound in the sample, measured by HPLC. Research-grade peptides are typically ≥98% pure.
Related Research & Documentation
